BRPI0518139A - formulações de gel de 4-hidróxi tamoxifeno - Google Patents

formulações de gel de 4-hidróxi tamoxifeno

Info

Publication number
BRPI0518139A
BRPI0518139A BRPI0518139-9A BRPI0518139A BRPI0518139A BR PI0518139 A BRPI0518139 A BR PI0518139A BR PI0518139 A BRPI0518139 A BR PI0518139A BR PI0518139 A BRPI0518139 A BR PI0518139A
Authority
BR
Brazil
Prior art keywords
tamoxifen
gel formulations
hydroxy
hydroxy gel
formulations
Prior art date
Application number
BRPI0518139-9A
Other languages
English (en)
Inventor
Valerie Masini-Eteve
Original Assignee
Besins Int Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04292447A external-priority patent/EP1647271A1/en
Application filed by Besins Int Lab filed Critical Besins Int Lab
Publication of BRPI0518139A publication Critical patent/BRPI0518139A/pt
Publication of BRPI0518139B1 publication Critical patent/BRPI0518139B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

FORMULAçõES DE GEL DE 4-HIDRóXI TAMOXIFENO. A presente invenção refere-se a composições farmacêuticas e géis que contêm (4-hidróxi tamoxifeno) e a métodos que utilizam os mesmos.
BRPI0518139-9A 2004-10-14 2005-10-13 Formulações de gel de 4-hidróxi tamoxifeno BRPI0518139B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP04292447.2 2004-10-14
EP04292447A EP1647271A1 (en) 2004-10-14 2004-10-14 4-Hydroxy tamoxifen gel formulations
US63835904P 2004-12-23 2004-12-23
US60/638,359 2004-12-23
PCT/EP2005/011654 WO2006040196A1 (en) 2004-10-14 2005-10-13 4-hydroxy tamoxifen gel formulations

Publications (2)

Publication Number Publication Date
BRPI0518139A true BRPI0518139A (pt) 2008-10-28
BRPI0518139B1 BRPI0518139B1 (pt) 2021-10-13

Family

ID=35501209

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518139-9A BRPI0518139B1 (pt) 2004-10-14 2005-10-13 Formulações de gel de 4-hidróxi tamoxifeno

Country Status (23)

Country Link
EP (1) EP1799201B1 (pt)
JP (1) JP5047800B2 (pt)
KR (1) KR101294947B1 (pt)
AT (1) ATE415156T1 (pt)
AU (1) AU2005293712B2 (pt)
BR (1) BRPI0518139B1 (pt)
CA (1) CA2582174C (pt)
CY (1) CY1110499T1 (pt)
DE (1) DE602005011314D1 (pt)
DK (1) DK1799201T3 (pt)
EA (1) EA011295B1 (pt)
ES (1) ES2318563T3 (pt)
GE (1) GEP20104889B (pt)
HR (1) HRP20090239T1 (pt)
IL (1) IL182298A (pt)
MA (1) MA28927B1 (pt)
MX (1) MX2007004371A (pt)
NO (1) NO338755B1 (pt)
PL (1) PL1799201T3 (pt)
PT (1) PT1799201E (pt)
SI (1) SI1799201T1 (pt)
TN (1) TNSN07139A1 (pt)
WO (1) WO2006040196A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10080760B2 (en) * 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
KR101304536B1 (ko) * 2011-06-03 2013-09-24 전남대학교산학협력단 4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 간질환의 치료 또는 예방용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
EP2050443B1 (en) * 2002-12-18 2017-05-24 Besins Healthcare Luxembourg SARL Reduction of breast density with 4-hydroxy tamoxifen
EP1572178B1 (en) * 2002-12-18 2006-05-03 Laboratoires Besins International Treatment of mastalgia with 4-hydroxy tamoxifen
CA2519980C (en) * 2003-04-01 2012-04-10 Laboratoires Besins International Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
CA2549824C (en) * 2003-12-15 2012-03-13 Laboratoires Besins International Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia
US20050208139A1 (en) * 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
AU2005227072B2 (en) * 2004-03-22 2010-08-19 Besins Healthcare Luxembourg Sarl Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1579856A1 (en) * 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen

Also Published As

Publication number Publication date
ES2318563T3 (es) 2009-05-01
SI1799201T1 (sl) 2009-06-30
HRP20090239T1 (en) 2009-06-30
MX2007004371A (es) 2007-06-07
ATE415156T1 (de) 2008-12-15
CA2582174C (en) 2013-01-29
PT1799201E (pt) 2009-02-26
EA200700834A1 (ru) 2007-10-26
EP1799201B1 (en) 2008-11-26
NO338755B1 (no) 2016-10-17
PL1799201T3 (pl) 2009-05-29
TNSN07139A1 (en) 2008-11-21
JP5047800B2 (ja) 2012-10-10
BRPI0518139B1 (pt) 2021-10-13
AU2005293712A1 (en) 2006-04-20
EA011295B1 (ru) 2009-02-27
EP1799201A1 (en) 2007-06-27
DK1799201T3 (da) 2009-03-30
MA28927B1 (fr) 2007-10-01
KR20070068366A (ko) 2007-06-29
AU2005293712B2 (en) 2011-04-21
WO2006040196A1 (en) 2006-04-20
JP2008525316A (ja) 2008-07-17
CA2582174A1 (en) 2006-04-20
IL182298A0 (en) 2007-07-24
NO20072463L (no) 2007-05-14
HK1103027A1 (en) 2007-12-14
IL182298A (en) 2013-01-31
GEP20104889B (en) 2010-02-10
CY1110499T1 (el) 2015-04-29
KR101294947B1 (ko) 2013-08-09
DE602005011314D1 (de) 2009-01-08

Similar Documents

Publication Publication Date Title
CR10528A (es) Proceso para producir poxvirus y composiciones de poxvirus
BR0315275A (pt) Anticorpos que se ligam a receptor de eritropoietina
BRPI0608604B8 (pt) moduladores de 2,3-dioxigenase de indolamina e composição farmacêutica
HN2002000291A (es) Alquinos como inhibidores de metodo proteinasa matriz
CR9942A (es) Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)
GT200600316A (es) Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
SV2001000004A (es) Difenil ureas w-carboxyaril sustituidas, composición farmacéutica que las comprende y su uso como inhibidores de raf quinasa
CR9746A (es) Bazedoxifene acetate formulations
BRPI0411528A (pt) uso de isomalte como prebiótico
MA28909B1 (fr) Quinazolines utiles en tant que modulateurs de canaux ioniques
CR9223A (es) 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas,asi como preparaciones farmaceuticas que las contienen
DE60225040D1 (de) Montelukast-granulatformulierung
GT200800276A (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
BRPI0716754A8 (pt) Composição à base de xantoxilina e a respectiva utilização em cosmética
HN2008001393A (es) Derivados de 1,2,4,5- tetrahidro -3h- benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
BRPI0512352A (pt) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas
BRPI0518904A2 (pt) formulaÇÕes de nepafenac tàpicas
DK1536836T3 (da) Topisk emulsionsgelsammensætning indeholdende diclofenacnatrium
ECSP045493A (es) Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a
UA87335C2 (en) Gel composition of 4-hydroxytamoxifen
BRPI0620229A8 (pt) formulação
BRPI0417205A (pt) composições farmacêuticas
ES2422173T3 (es) Composiciones que contienen aecuorina y procedimientos de uso de las mismas
CY1110499T1 (el) Παρασκευασματα γελης 4-υδροξυ ταμοξιφενης
PA8795401A1 (es) Asociacion entre un antiaterotrombotico y un inhibidor de la enzima de conversion de la angiotensina

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BESINS HEALTHCARE LUXEMBOURG SARL (LU)

B25G Requested change of headquarter approved

Owner name: BESINS HEALTHCARE LUXEMBOURG SARL (LU)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/10/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.